Found 1697 clinical trials
Inflammatory Bowel Disease (IBD) Research Registry
Information obtained from the Inflammatory Bowel Disease Registry will allow a better classification of disease and factors that influence the natural course of disease; which may lead to a better understanding of the pathogenesis of IBD and may permit the development of better therapies and the potential for preventive therapies.
- 0 views
- 19 Feb, 2024
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort
The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …
- 0 views
- 19 Feb, 2024
French COVID Cohort
Ebola), and viruses that affect the central nervous system (CNS) such as TBEV & Nipah require investigation to understand pathogen biology and pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is widespread, and treatments to control potentially deleterious host responses are lacking. In order to develop …
- 0 views
- 19 Feb, 2024
LIPAD - LRRK2 International Parkinson's Disease Study
Based on current knowledge, it can be assumed that there are several causes and that the causes may be differ between patients; this makes research into the pathogenesis and possible therapies very difficult. In the case of monogenic Parkinson's diseases, which are due to changes in one gene (e.g. LRRK2), …
- 0 views
- 19 Feb, 2024
Predictive Factors COVID-19 Patients
This is a monocentric retro-prospective observational study that will be conducted on all COVID19 positive patients hospitalized at the S. Gerardo Hospital in Monza.
- 0 views
- 19 Feb, 2024
A Study for Post-Marketing Surveillance of Azilsartan Medoxomil in the Treatment of Adult Participants With Essential Hypertension in South Korea
The purpose of this study is to evaluate the safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on the precaution in the use, ADRs already known, non-serious ADRs and other …
- 0 views
- 19 Feb, 2024
A Study for Post-marketing Surveillance of Azilsartan Medoxomil/Chlorthalidone Fixed Dose Combination (FDC) in the Treatment of Participants With Essential Hypertension in South Korea
The purpose of this study is to evaluate the safety by assessing all serious and non-serious adverse events (AEs), irrespective of relatedness or expectedness, as well as other safety parameters including laboratory values, serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on …
- 0 views
- 19 Feb, 2024
Proton Radiation Therapy Registry
The Johns Hopkins Proton Therapy center is establishing a registry to capture the full 3D radiation dosimetry delivered to the patient, baseline clinical data, and disease, toxicity and quality of life outcomes. The goal is to have all patients treated at the proton center to be included in the registry …
- 0 views
- 19 Feb, 2024
French Observatory of ElectroConvulsive Therapy (ECT)
Since the 30s, ECT has been a psychiatric treatment mainly used for drug-resistant depressive illnesses. Clinical studies have shown its therapeutic efficiency compared to standard treatments also in other psychiatric illnesses. Although efficient, ECTs also induce side effects. In France, there is currently no consensus on providing the suitest medical …
- 0 views
- 19 Feb, 2024
Comparative Effectiveness of Targeted Therapy in RA Patients
The objective of a multicenter prospective observational study is to compare effectiveness and safety of biologic disease-modifying antirheumatic drugs and small molecular inhibitors in patients with moderately to severely active rheumatoid arthritis patients who have had an inadequate response or intolerace to methotrexate.
- 0 views
- 19 Feb, 2024